Stocks got off to a slightly lower start Tuesday as investors digested a stream of earnings reports, including results from Dow components Johnson & Johnson JNJ, -0.84% and Goldman Sachs Group Inc. GS, +2.42% The Dow Jones Industrial Average DJIA, +0.07% fell around 7 points, or less than 0.
1%, to 27,352, while the S&P 500 SPX, -0.03% was off 0.1% at 3,011.12. The Nasdaq Composite COMP, -0.08% fell 0.1% to 8,245.28. All three major indexes eked out record finished in subdued trading on Monday. Shares of Goldman Sachs were up 0.9%, while Johnson & Johnson shares fell 1.7%. Both companies topped earnings forecasts.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
World stocks mark time ahead of U.S. data, earningsGlobal stocks struggled to cling to recent gains on Tuesday and the dollar linge...
Source: Reuters - 🏆 2. / 97 Read more »
European stocks set to open higher despite China slowdown fearsEuropean stocks are set to rise Monday, despite worries China's economy is slowing amid a trade war with the U.S.
Source: CNBC - 🏆 12. / 72 Read more »
U.S. stocks set to tread water as investors await trio of bank earningsU.S. stock futures trade on either side of unchanged Tuesday morning a day after major equity indexes eked out a round of fresh all-time closing highs as Wall Street braces for a trifecta of bank earnings — likely to set the tone for trading on the day.
Source: MarketWatch - 🏆 3. / 97 Read more »
European stocks seen under pressure as investors await earningsEuropean stocks are set to begin Tuesday's session mixed as traders monitor a slew of earnings reports.
Source: CNBC - 🏆 12. / 72 Read more »
Cannabis stocks rally after FDA says it will speed up effort to create rules for CBDCannabis stocks were mostly higher on Monday, after the U.S. Food and Drug Administration said it is expediting its effort to create a regulatory framework... Interesting to watch. How much of this is a hype? Is everything already priced in and the current rally is purely based on the future/speculation?
Source: MarketWatch - 🏆 3. / 97 Read more »